Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
| Revenue (Most Recent Fiscal Year) | $627.24M |
| Net Income (Most Recent Fiscal Year) | $-177.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.31 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.23 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -25.21% |
| Net Margin (Trailing 12 Months) | -29.95% |
| Return on Equity (Trailing 12 Months) | -21.19% |
| Return on Assets (Trailing 12 Months) | -13.47% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.20 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.30 |
| Inventory Turnover (Trailing 12 Months) | 10.61 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.54 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.52 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.59 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 183.76M |
| Free Float | 183.73M |
| Market Capitalization | $5.32B |
| Average Volume (Last 20 Days) | 1.77M |
| Beta (Past 60 Months) | 0.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.02% |
| Percentage Held By Institutions (Latest 13F Reports) | 70.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |